Journal: PLoS ONE

Article Title: Innate Immune Responses after Airway Epithelial Stimulation with Mycobacterium bovis Bacille-Calmette Guérin

doi: 10.1371/journal.pone.0164431

Figure Lengend Snippet: (A) CXCL8 and (B) IL-6 production from epithelial cells stimulated with BCG in combination with IL-17A and/or IFN-γ for 0, 24, 48 and 72 hours, MOI 1:1. The 72 hours time points are in addition represented as bar graphs for (C) CXCL8 and (D) IL-6. The results are depicted as mean ± SD of three experiments. Means were compared with one way ANOVA followed by multiple comparisons test with Tukey’s correction and significance was accepted at *p < 0.05, **p< 0.01, or ***p < 0.001.

Article Snippet: For the cytokine stimulation experiments, recombinant IL-17A and/or IFNγ (10 ng/mL, 7955-IL, 285-IF, RnD Systems, Denmark) were added to the bottom insert 30 min before the addition of BCG.

Techniques:

Journal: PLoS ONE

Article Title: Innate Immune Responses after Airway Epithelial Stimulation with Mycobacterium bovis Bacille-Calmette Guérin

doi: 10.1371/journal.pone.0164431

Figure Lengend Snippet: Primary neutrophils were stimulated with BCG for one, two and three hours in the presence of IL-17A and/or IFN-γ. (A) NETs were studied in a light microscope after 2 hours and stained with DAPI and (B) large NET structures were observed in addition to single NETs. (C) Quantification of NETs was performed with Picogreen assay on cell supernatants after 3 hours and (D) over time at 1, 2 and 3 hours. Results are depicted as mean ± SD from a total of 4 donors. Means of samples were were compared with negative control using ANOVA followed by Dunnet’s multiple comparisons test and significance was accepted at *p < 0.05, **p< 0.01, or ***p < 0.001. Bars represent 25 μm (A, B left panel) or 100 μm (B, right panel)

Article Snippet: For the cytokine stimulation experiments, recombinant IL-17A and/or IFNγ (10 ng/mL, 7955-IL, 285-IF, RnD Systems, Denmark) were added to the bottom insert 30 min before the addition of BCG.

Techniques: Light Microscopy, Staining, Picogreen Assay, Negative Control

Journal: Journal of Inflammation Research

Article Title: Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A

doi: 10.2147/JIR.S100940

Figure Lengend Snippet: In vitro binding parameters of ixekizumab to human, cynomolgus monkey, and rabbit IL-17A determined using surface plasmon resonance

Article Snippet: Recombinant mouse IL-17A (R&D Systems) was used as a positive control for these experiments.

Techniques: In Vitro, Binding Assay

Journal: Nature communications

Article Title: Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.

doi: 10.1038/s41467-023-44270-3

Figure Lengend Snippet: Fig. 5 | IL-17A stimulates the secretion of CXCL16 from leukemia cells, pro- moting the differentiation and migration of Th17 cells. a B220+ cells and Th17 cells in the BM niche in WT mice and BCR-ABLtTA mice (n = 3 mice per group) were subjected to immunofluorescence staining. Representative images were shown. b The numbers of Th17 cells migrating to culture medium or to leukemia cells treated with or without 50 ng/ml rhIL-17A were determined by cell counting and FCS analysis. c Real-time PCR analysis of the relative mRNA levels of chemokine genes in SupB15 (left) and BV173 cells (right) treated with rhIL-17A (100 ng/ml) or PBS control. d The human IL-5, CXCL5, CCL5 and CXCL16 levels in the culture supernatant of SupB15 cells treated with or without rhIL-17A (100 ng/ml) were measured by ELISA. e The CXCL16 concentrations in the serum of BCR-ABLtTA mice and WT mice (n = 5 mice per group) were quantified with a Mouse Chemokine Assay Q1 (Raybiotech). f The CXCL16 concentrations in the serum of HDs (n = 7 samples)

Article Snippet: Three days after transplantation, 70mg/kg imatinib (Sigma–Aldrich, SML1027, p.o., once a day), 5mg/kg anti-IL-17A neutralizing antibody (Bio X Cell, BP0173, i.v., twice a week), or 0.5mg/kg anti-mouse CXCL16 neutralizing antibody (R&D,MAB503, i.v., twice aweek)were administered for 3 consecutive weeks.

Techniques: Migration, Staining, Cell Counting, Real-time Polymerase Chain Reaction, Control, Enzyme-linked Immunosorbent Assay